Rizatriptan Benzoate Tablet, Orally Disintegrating
NDC Package 57237-086-63
Package Information
Rizatriptan Benzoate tablets is rizatriptan is used to treat migraines. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 57237-086 and is authorized under FDA application ANDA203062.
Identification & Billing
- RxCUI: 312837 - rizatriptan benzoate 10 MG Disintegrating Oral Tablet
- RxCUI: 312837 - rizatriptan 10 MG Disintegrating Oral Tablet
- RxCUI: 312837 - rizatriptan 10 MG (as rizatriptan benzoate 14.53 MG) Disintegrating Oral Tablet
- RxCUI: 312839 - rizatriptan benzoate 5 MG Disintegrating Oral Tablet
- RxCUI: 312839 - rizatriptan 5 MG Disintegrating Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57237 - Rising Pharma Holdings, Inc.
- 57237-086 - Rizatriptan Benzoate
- 57237-086-63 - 3 BLISTER PACK in 1 CARTON / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
- 57237-086 - Rizatriptan Benzoate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57237-086-63 identifies a specific commercial package of 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack of Rizatriptan Benzoate, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This tablet, orally disintegrating is formulated for oral use and contains rizatriptan benzoate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on July 01, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Rizatriptan is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications. Rizatriptan belongs to a class of drugs known as triptans. It affects a certain natural substance (serotonin) that causes narrowing of blood vessels in the brain. It may also relieve pain by affecting certain nerves in the brain. Rizatriptan does not prevent future migraines or lessen how often you get migraine attacks.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57237008663. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.